Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Eli S. Rosenberg, Elizabeth Dufort, Tomoko Udo, et al.
JAMA (2020) Vol. 323, Iss. 24, pp. 2493-2493
Open Access | Times Cited: 1147

Showing 26-50 of 1147 citing articles:

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean‐Christophe Lagier, Matthieu Million, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 36, pp. 101791-101791
Open Access | Times Cited: 254
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 5, pp. 601-621
Open Access | Times Cited: 250
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements
Praveen Kolimi, Sagar Narala, Dinesh Nyavanandi, et al.
Cells (2022) Vol. 11, Iss. 15, pp. 2439-2439
Open Access | Times Cited: 233
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Xuping Xie, Antonio E. Muruato, Xianwen Zhang, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 287-296
Closed Access | Times Cited: 220
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
Min Seo Kim, Min Ho An, Won Jun Kim, et al.
PLoS Medicine (2020) Vol. 17, Iss. 12, pp. e1003501-e1003501
Open Access | Times Cited: 203
Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future
Olayinka O. Ogunleye, Debashis Basu, Debjani Mueller, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 191
Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Kathleen Chiotos, Molly Hayes, David W. Kimberlin, et al.
Journal of the Pediatric Infectious Diseases Society (2020) Vol. 9, Iss. 6, pp. 701-715
Open Access | Times Cited: 183
Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19
Stephen M. Smith, Avinash S. Boppana, Julie A. Traupman, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 1, pp. 409-415
Open Access | Times Cited: 170
Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment
Sebastiano Cicco, Gerolamo Cicco, Vito Racanelli, et al.
Mediators of Inflammation (2020) Vol. 2020, pp. 1-25
Open Access | Times Cited: 165
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
Chris R. Triggle, Devendra Bansal, Hong Ding, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 165
Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
Yahya Mahamat‐Saleh, Thibault Fiolet, Mathieu E. Rebeaud, et al.
BMJ Open (2021) Vol. 11, Iss. 10, pp. e052777-e052777
Open Access | Times Cited: 164
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
Peter A. McCullough, Ronan J. Kelly, Gaetano Ruocco, et al.
The American Journal of Medicine (2020) Vol. 134, Iss. 1, pp. 16-22
Open Access | Times Cited: 162
Factors leading to high morbidity and mortality of COVID‐19 in patients with type 2 diabetes
Aman Rajpal, Leili Rahimi, Faramarz Ismail‐Beigi
Journal of Diabetes (2020) Vol. 12, Iss. 12, pp. 895-908
Open Access | Times Cited: 158
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
Risk factors and outcome of COVID-19 in patients with hematological malignancies
José Luís Piñana, Rodrigo Martino, Irene García‐García, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 144
Natural history of COVID-19 and therapeutic options
Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 12, pp. 1159-1184
Closed Access | Times Cited: 143
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
Andrew Ip, Donald A. Berry, Eric Hansen, et al.
PLoS ONE (2020) Vol. 15, Iss. 8, pp. e0237693-e0237693
Open Access | Times Cited: 140
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
Edina Cenko, Lina Badimón, Raffaele Bugiardini, et al.
Cardiovascular Research (2021) Vol. 117, Iss. 14, pp. 2705-2729
Open Access | Times Cited: 127
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress
Ryan Chang, Abrar Mamun, Abishai Dominic, et al.
Frontiers in Physiology (2021) Vol. 11
Open Access | Times Cited: 114
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
Ilad Alavi Darazam, Shervin Shokouhi, Mohamad Amin Pourhoseingholi, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 108
Intensive care management of patients with COVID-19: a practical approach
Ludhmila Abrahão Hajjar, Isabela Bispo Santos da Silva Costa, Stéphanie Itala Rizk, et al.
Annals of Intensive Care (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 106

Scroll to top